2014-06-18T13:17:50-05:00 2013-09-30 GRANT THORNTON LLP 666 THIRD AVENUE NEW YORK NY 100174057 990 2012-10-01 133163817 THE FOUNDATION FOR AIDS RESEARCH % BRADLEY JENSEN FOUN 2128061600 120 wall street 13TH FLOOR Suite NEW YORK NY 100053908 Please update 2125990100 2014-06-18 true 2125990100 2012 2015-11-30 17:44:51Z AMFAR KEVIN FROST 120 WALL STREET 13TH FLOOR new york NY 10005 50139259 false X WWW.AMFAR.ORG X 1983 NY amfar is dedicated to ending the global aids epidemic through innovative research. 20 20 91 168 0 33247849 38582579 0 0 1178972 980398 -7234513 -9648345 27192308 29914632 8086344 7997283 0 0 8864151 9333804 491117 470337 4996086 11261191 11457241 28702803 29258665 -1510495 655967 40388195 50024337 9636091 18892314 30752104 31132023 X THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARC false false 8102469 4075650 0 RESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. For further details, see Schedule o. 6010188 2581709 0 TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. For further details, see Schedule o. 3426418 0 0 EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research on HIV/AIDS. For further details, see Schedule O. 2363749 1132282 0 GMT Initiative 2039872 207642 0 public policy 4403621 1339924 0 21942696 true true false true false false false true false true true true false false true true true false false true true true false true true false false true false true false false false false false false false false true false false false false false false false false true 113 0 true 91 true false true TH false false false true true false false false false X 20 20 false false false false false false false true true false false true true true true true true true true false AL AK AZ AR CA CT FL GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WV WI X X BRADLEY JENSEN 2128061703 120 WALL STREET 13TH FLOOR new york NY 100053908 Mathilde Krim PhD 1.0 X X Kenneth Cole 1.0 X X Patricia J Matson 1.0 X X John C Simons 1.0 X X Wallace Sheft CPA 1.0 X X Mervyn F Silverman MDMPH 1.0 X X Arlen H Andelson 1.0 X Harry Belafonte 1.0 X David Bohnett 1.0 X Zev Braun 1.0 X Jonathan S Canno 1.0 X Donald Capoccia 1.0 X R Martin Chavez PhD 1.0 X Jane B Eisner 1.0 X T Ryan Greenawalt 1.0 X Regan Hofmann 1.0 X Michael J Klingensmith 1.0 X Michele V McNeill PharmD 1.0 X Edward Milstein 1.0 X Cindy Rachofsky 1.0 X Vincent A Roberti 1.0 X Bill Roedy 1.0 X Alan D Schwartz 1.0 X Diana L Taylor 1.0 X Kevin Wendle 1.0 X Kevin McClatchy 1.0 X Raymond F Schinazi PhD 1.0 X Kevin Frost 40.0 X 385700 0 98183 Bradley Jensen 40.0 X 217845 0 46789 John F Logan JD PhD 40.0 X 203482 0 24532 Rowena Johnston 40.0 X 166901 0 21937 Edward Donnelly 40.0 X 133796 0 18839 Gregory L Boroff 40.0 X 228217 0 26419 Christopher Collins 40.0 X 192518 0 32356 Annette Sohn 40.0 X 200613 0 19635 AnnMarie Shannahan 40.0 X 194344 0 23872 Eric Muscatell 40.0 X 157089 0 21477 Andrew McInnes 40.0 X 134850 0 41195 Anthony Ancona 40.0 X 155133 0 14211 Susan Doster 40.0 X 132775 0 19478 Bennah Serfaty 40.0 X 120255 0 39311 2623518 0 448234 19 false true false JOSH WOODS PRODUCTION 39 WEST 14TH STREET SUITE 504 NEW YORK NY 10011 events production 448921 AAB PRODUCTIONS 64 ALLEN ROAD 5TH FLOOR NEW YORK NY 10002 EVENTS PRODUCTION 252500 GRANT THORNTON LLP 1901 W MEYERS ROAD SUITE 455 OAKBROOK TERRACE IL 60181 ACCOUNTING & AUDIT 151260 THE MORRIS KING COMPANY LLC 101 FIFTH AVENUE 8TH FLOOR NEW YORK NY 10003 PUBLIC RELATIONS 148000 GLOBAL HEALTH INSTITUTE LLC 5530 WISCONSIN AVENUE SUITE 1255 CHEVY CHASE MD 20815 PROGRAM DEVELOPMENT 110368 6 461323 26085758 4641815 7393683 104103 38582579 0 708016 708016 0 47277 47277 0 0 0 9227075 8954693 272382 272382 272382 1357200 26085758 11216365 -9859165 -9859165 0 103590 53569 157159 157159 LIST RENTALS 900099 5477 5477 MISCELLANEOUS INCOME 900099 907 907 6384 29914632 -8667947 X 3633934 3633934 0 4363349 4363349 0 2291708 1514295 441710 335703 0 5216798 3553662 392009 1271127 296141 199278 23426 73437 1048235 668360 133335 246540 480922 309774 56428 114720 0 185935 147812 19932 18191 167426 167426 62807 62807 470337 470337 164418 164418 1298183 924659 49164 324360 476903 473959 1184 1760 109631 55430 7621 46580 174371 128295 23985 22091 0 1231775 869859 159658 202258 836636 394275 881 441480 0 858596 746815 8077 103704 8 8 0 415252 293370 53847 68035 197026 139196 25549 32281 PROGRAM MATERIALS 1425070 1425070 0 0 POSTAGE & SHIPPING 761994 345771 5618 410605 PRINTING 745975 275663 745 469567 PROGRAM TECHNICAL SUPPORT 598873 598873 0 0 1746362 818190 584862 343310 29258665 21942696 2319883 4996086 X 999371 377734 621637 6129973 8001602 216445 539347 203639 205706 3725105 10267012 0 0 0 0 0 0 75665 133906 705507 1401620 5156241 3180930 1888607 1975311 23016384 23656458 4233643 3169232 0 0 0 0 193227 674143 40388195 50024337 1732740 1688090 1713122 2200512 5428345 13321993 0 0 0 0 0 0 0 0 0 0 761884 1681719 9636091 18892314 X 21921458 23555115 8493158 7236209 337488 340699 30752104 31132023 40388195 50024337 X 655967 -246161 -29887 X false true X true true true X 20760601 22553697 22876129 33247849 38582579 138020855 0 0 20760601 22553697 22876129 33247849 38582579 138020855 5256686 132764169 643473 668573 951963 897974 755293 3917276 0 155966 2756152 1735330 1624966 1467174 7739588 149677719 0 0.88700 0.90865 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false false false true 187171 187171 false false Lobbying Expenses Part II-B The Foundation for AIDS Research developed an Action Agenda to End AIDS that identified critical decisions that need to be made to advance evidence based AIDS policies. We created a variety of issue briefs on topics such as the potential impact of various budget scenarios on global health services, and policy priorities to address the HIV epidemic among gay men in the US. These issue briefs were shared with Capitol Hill staff and members of the Administration. amfAR met regularly with staff to members of Congress and with Administration staff, and we provided input to the Administration on development of the PEPFAR Blueprint for an AIDS Free Generation. amfAR sponsored several briefings on Capitol Hill on AIDS policy and research issues. amfAR uses these briefings as an educational tool. 149840 X Donated Items, Inventory etc. true 520804 3211 20742 100871 443886 464356 4341 52107 520804 561083 5978 -2705 100000 464356 516826 8258 35999 561083 470065 9378 37383 516826 0.76754 0.23246 false false 2101499 648256 1453243 305895 249847 56048 2748847 2282827 466020 1975311 BENEFICIAL INTEREST IN TRUST 3169232 F 3169232 0 LONG TERM LEASE LIABILITY 1535854 SECTION 457 RETIREMENT LIABILITIES 145865 1681719 X 29942921 -246161 304337 -29887 28289 29914632 29914632 29563002 304337 304337 29258665 29258665 Endowments Part V, Line 4 AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors. FIN 48 Income taxes Amfar follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement, classification, interest and penalties, and disclosure. As of September 30, 2013, amfar does not believe that there are any uncertain tax positions within its financial statements. Amfar has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The tax years ended 2010, 2011, 2012, and 2013 are still open to audit for both federal and state purposes. Collections of Art, Histocial Treasures, or other similar assets Part III, Line 4 AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them. RECONCILIATION OF REVENUE PART XI, LINE 2D CHANGE IN VALUE OF THIRD PARTY TRUST ($29,887) true Central America and the Caribbean Grantmaking N/A 177540 East Asia and the Pacific 1 19 Grantmaking N/A 2604045 Europe (Including Iceland and Greenland) Grantmaking N/A 656607 Middle East and North Africa Grantmaking N/A 20000 North America Grantmaking N/A 150000 Russia and the Newly Independent States Grantmaking N/A 97179 South America Grantmaking N/A 249759 South Asia Grantmaking N/A 56965 Sub-Saharan Africa Grantmaking N/A 351253 East Asia and the Pacific Program Services therapeutics research 2889590 Europe (Including Iceland and Greenland) Fundraising 5474457 North America Fundraising 435325 South America Fundraising 900829 1 19 1 19 14063549 14063549 Central America and the Caribbean GMT INITIATIVE 12000 wire transfe Central America and the Caribbean GMT INITIATIVE 17500 wire transfe Central America and the Caribbean GMT INITIATIVE 17500 wire transfe Central America and the Caribbean GMT INITIATIVE 17500 wire transfe Central America and the Caribbean GMT INITIATIVE 14700 wire transfe Central America and the Caribbean GMT INITIATIVE 19250 wire transfe Central America and the Caribbean GMT INITIATIVE 17500 wire transfe Central America and the Caribbean GMT INITIATIVE 17496 wire transfe Central America and the Caribbean GMT INITIATIVE 26594 wire transfe Central America and the Caribbean GMT INITIATIVE 17500 wire transfe East Asia and the Pacific BASIC RESEARCH 15626 wire transfe East Asia and the Pacific BASIC RESEARCH 26043 wire transfe East Asia and the Pacific BASIC RESEARCH 10000 wire transfe East Asia and the Pacific TREAT ASIA 6330 wire transfe East Asia and the Pacific TREAT ASIA 7690 wire transfe East Asia and the Pacific TREAT ASIA 25637 wire transfe East Asia and the Pacific TREAT ASIA 12250 wire transfe East Asia and the Pacific TREAT ASIA 14250 wire transfe East Asia and the Pacific TREAT ASIA 19110 wire transfe East Asia and the Pacific TREAT ASIA 19050 wire transfe East Asia and the Pacific TREAT ASIA 18180 wire transfe East Asia and the Pacific TREAT ASIA 8170 wire transfe East Asia and the Pacific TREAT ASIA 9150 wire transfe East Asia and the Pacific TREAT ASIA 14250 wire transfe East Asia and the Pacific TREAT ASIA 132059 wire transfe East Asia and the Pacific TREAT ASIA 24042 wire transfe East Asia and the Pacific TREAT ASIA 11494 wire transfe East Asia and the Pacific TREAT ASIA 16177 wire transfe East Asia and the Pacific TREAT ASIA 20529 wire transfe East Asia and the Pacific TREAT ASIA 17576 wire transfe East Asia and the Pacific TREAT ASIA 21445 wire transfe East Asia and the Pacific TREAT ASIA 23404 wire transfe East Asia and the Pacific TREAT ASIA 14459 wire transfe East Asia and the Pacific TREAT ASIA 7695 wire transfe East Asia and the Pacific TREAT ASIA 7087 wire transfe East Asia and the Pacific TREAT ASIA 14009 wire transfe East Asia and the Pacific TREAT ASIA 15843 wire transfe East Asia and the Pacific TREAT ASIA 165747 wire transfe East Asia and the Pacific TREAT ASIA 207232 wire transfe East Asia and the Pacific TREAT ASIA 243438 wire transfe East Asia and the Pacific TREAT ASIA 35051 wire transfe East Asia and the Pacific TREAT ASIA 7125 wire transfe East Asia and the Pacific TREAT ASIA 5550 wire transfe East Asia and the Pacific TREAT ASIA 6525 wire transfe East Asia and the Pacific TREAT ASIA 5175 wire transfe East Asia and the Pacific TREAT ASIA 7500 wire transfe East Asia and the Pacific TREAT ASIA 6450 wire transfe East Asia and the Pacific TREAT ASIA 6900 wire transfe East Asia and the Pacific TREAT ASIA 7350 wire transfe East Asia and the Pacific TREAT ASIA 6300 wire transfe East Asia and the Pacific TREAT ASIA 6225 wire transfe East Asia and the Pacific TREAT ASIA 19586 wire transfe East Asia and the Pacific TREAT ASIA 10499 wire transfe East Asia and the Pacific TREAT ASIA 20000 wire transfe East Asia and the Pacific TREAT ASIA 15150 wire transfe East Asia and the Pacific TREAT ASIA 17524 wire transfe East Asia and the Pacific TREAT ASIA 18900 wire transfe East Asia and the Pacific TREAT ASIA 15800 wire transfe East Asia and the Pacific TREAT ASIA 17850 wire transfe East Asia and the Pacific TREAT ASIA 12900 wire transfe East Asia and the Pacific TREAT ASIA 20000 wire transfe East Asia and the Pacific TREAT ASIA 14775 wire transfe East Asia and the Pacific TREAT ASIA 15050 wire transfe East Asia and the Pacific TREAT ASIA 20000 wire transfe East Asia and the Pacific TREAT ASIA 20000 wire transfe East Asia and the Pacific TREAT ASIA 20000 wire transfe East Asia and the Pacific TREAT ASIA 20000 wire transfe East Asia and the Pacific TREAT ASIA 20000 wire transfe East Asia and the Pacific TREAT ASIA 100000 wire transfe East Asia and the Pacific TREAT ASIA 6747 wire transfe East Asia and the Pacific TREAT ASIA 9433 wire transfe East Asia and the Pacific BASIC RESEARCH 286064 wire transfe East Asia and the Pacific TREAT ASIA 34622 wire transfe East Asia and the Pacific TREAT ASIA 41667 wire transfe East Asia and the Pacific TREAT ASIA 36098 wire transfe East Asia and the Pacific TREAT ASIA 150000 wire transfe East Asia and the Pacific TREAT ASIA 19833 wire transfe East Asia and the Pacific TREAT ASIA 6000 wire transfe East Asia and the Pacific TREAT ASIA 6150 wire transfe East Asia and the Pacific TREAT ASIA 9453 wire transfe East Asia and the Pacific TREAT ASIA 26775 wire transfe East Asia and the Pacific TREAT ASIA 19042 wire transfe East Asia and the Pacific TREAT ASIA 11315 wire transfe East Asia and the Pacific GMT INITIATIVE 18000 wire transfe East Asia and the Pacific GMT INITIATIVE 17000 wire transfe East Asia and the Pacific GMT INITIATIVE 18135 wire transfe East Asia and the Pacific TREAT ASIA 15167 wire transfe East Asia and the Pacific TREAT ASIA 40000 wire transfe East Asia and the Pacific TREAT ASIA 15964 wire transfe East Asia and the Pacific TREAT ASIA 15000 wire transfe East Asia and the Pacific TREAT ASIA 5625 wire transfe East Asia and the Pacific TREAT ASIA 5625 wire transfe East Asia and the Pacific TREAT ASIA 5625 wire transfe East Asia and the Pacific TREAT ASIA 11250 wire transfe East Asia and the Pacific TREAT ASIA 11250 wire transfe East Asia and the Pacific TREAT ASIA 15000 wire transfe East Asia and the Pacific TREAT ASIA 11250 wire transfe East Asia and the Pacific TREAT ASIA 15000 wire transfe East Asia and the Pacific TREAT ASIA 79118 wire transfe East Asia and the Pacific TREAT ASIA 15000 wire transfe East Asia and the Pacific TREAT ASIA 9820 wire transfe East Asia and the Pacific TREAT ASIA 5650 wire transfe East Asia and the Pacific TREAT ASIA 14702 wire transfe East Asia and the Pacific TREAT ASIA 39029 wire transfe Europe (Including Iceland and Greenland) BASIC RESEARCH 26043 wire transfe Europe (Including Iceland and Greenland) BASIC RESEARCH 39062 wire transfe Europe (Including Iceland and Greenland) BASIC RESEARCH 10000 wire transfe Europe (Including Iceland and Greenland) BASIC RESEARCH 90765 wire transfe Europe (Including Iceland and Greenland) BASIC RESEARCH 159732 wire transfe Europe (Including Iceland and Greenland) BASIC RESEARCH 120000 wire transfe Europe (Including Iceland and Greenland) BASIC RESEARCH 120000 wire transfe Europe (Including Iceland and Greenland) PUBLIC POLICY 20000 wire transfe Europe (Including Iceland and Greenland) GMT INITIATIVE 14280 wire transfe Europe (Including Iceland and Greenland) GMT INITIATIVE 12000 wire transfe Europe (Including Iceland and Greenland) GMT INITIATIVE 14920 wire transfe Europe (Including Iceland and Greenland) GMT INITIATIVE 15000 wire transfe Europe (Including Iceland and Greenland) GMT INITIATIVE 20000 wire transfe Middle East and North Africa GMT INITIATIVE 20000 wire transfe North America GMT INITIATIVE 20000 wire transfe North America PREVENTION SCIENCE OUTREACH 130000 wire transfe Russia and the Newly Independent States GMT INITIATIVE 12000 wire transfe Russia and the Newly Independent States GMT INITIATIVE 14982 wire transfe Russia and the Newly Independent States GMT INITIATIVE 15050 wire transfe Russia and the Newly Independent States GMT INITIATIVE 14995 wire transfe Russia and the Newly Independent States GMT INITIATIVE 19952 wire transfe Russia and the Newly Independent States GMT INITIATIVE 20200 wire transfe South America GMT INITIATIVE 20000 wire transfe South America GMT INITIATIVE 20000 wire transfe South America GMT INITIATIVE 20000 wire transfe South America GMT INITIATIVE 20000 wire transfe South America GMT INITIATIVE 19900 wire transfe South America GMT INITIATIVE 19859 wire transfe South America GMT INITIATIVE 20000 wire transfe South America GMT INITIATIVE 14440 wire transfe South America GMT INITIATIVE 15000 wire transfe South America GMT INITIATIVE 17494 wire transfe South America GMT INITIATIVE 24066 wire transfe South America PREVENTION SCIENCE OUTREACH 35000 wire transfe South Asia GMT INITIATIVE 11959 wire transfe South Asia TREAT ASIA 13931 wire transfe South Asia TREAT ASIA 18750 wire transfe South Asia TREAT ASIA 18750 wire transfe South Asia TREAT ASIA 5625 wire transfe Sub-Saharan Africa GMT INITIATIVE 20000 wire transfe Sub-Saharan Africa GMT INITIATIVE 15000 wire transfe Sub-Saharan Africa GMT INITIATIVE 20000 wire transfe Sub-Saharan Africa GMT INITIATIVE 18500 wire transfe Sub-Saharan Africa GMT INITIATIVE 22000 wire transfe Sub-Saharan Africa GMT INITIATIVE 20000 wire transfe Sub-Saharan Africa GMT INITIATIVE 19789 wire transfe Sub-Saharan Africa GMT INITIATIVE 19980 wire transfe Sub-Saharan Africa GMT INITIATIVE 20000 wire transfe Sub-Saharan Africa GMT INITIATIVE 20000 wire transfe Sub-Saharan Africa GMT INITIATIVE 19984 wire transfe Sub-Saharan Africa GMT INITIATIVE 20000 wire transfe Sub-Saharan Africa GMT INITIATIVE 20000 wire transfe Sub-Saharan Africa GMT INITIATIVE 10000 wire transfe Sub-Saharan Africa GMT INITIATIVE 26000 wire transfe Sub-Saharan Africa PUBLIC POLICY 60000 wire transfe 159 false false false false false false Foreign Activities Part I, Line 2 International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period. foreign activities Part I, Line 3, Column D The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives. Foreign Activities - Status of Grantees The Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 159 charities supported are presumed to be the equivalent of U.S. charities. X X X X X X true aab productions 387 Grant Street Suite K705 New York NY 10002 Fundraising Event/Prod false 17864320 245067 17619253 john mini consulting inc 707 Savannah Road Lewes DE 199581521 direct mail false 1731016 95150 1635866 public interest communications 7700 Leesburg Pike Falls Church VA 22043 tele marketing false 54024 70572 -16548 Eidolon Communications INc 15 Maiden Lane Suite 1401 New York NY 10038 DIRECT MAIL false 199443 47700 151743 telefund inc PO Box 120557 Boston MA 02111 tele marketing false 18868 16231 2637 sanky communications inc 589 Eight Avenue 10th Floor New York NY 10018 counseling false 417841 102434 315407 20285512 577154 19708358 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VA WA WV WI Cannes 12526496 12085496 441000 0 0 746885 543201 3422020 Dallas 4507778 4407378 100400 0 0 46894 156114 2273065 14 10408684 9592884 815800 0 0 744868 228413 3054905 27442958 26085758 1357200 0 0 1538647 927728 8749990 11216365 -9859165 Schedule G, Part I The Foundation for AIDS Research actually paid out $470,337 in fundraising expenses for the year ending September 30, 2013. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $577,154. Of that $577,154, only $470,337 was paid for fundraising services, the remaining $106,817 was paid for event production services. In the interests of clarity, the foundation would also like to make clear that the compensation reported as having been paid to the professional fundraisers reported on Schedule G is reported on a fiscal year basis. Some of those same fundraisers are reported on the foundation's top 5 highest paid independent contractors list (in Schedule O). In compliance with the instructions to the Form 990, compensation reported for Part VII (and listed in Schedule O) is reported on a calendar year basis. Accordingly, amounts on Part VII and Schedule G will not reconcile. true The Aaron Diamond AIDS Research Center 455 First Avenue 7th Floor New York NY 10016 133540234 501(c)(3) 15626 BASIC RESEARCH University of California Los Angeles 11000 Kinross Avenue Suite 102 Los Angeles CA 900951406 956006143 501(c)(3) 7143 BASIC RESEARCH University of California San Francisco 333 California Street Suite 315 San Francisco CA 94118 946036493 501(c)(3) 72000 BASIC RESEARCH Case Western Reserve University School of Medicin 10900 Euclid Avenue Cleveland OH 44106 341018992 501(c)(3) 62479 BASIC RESEARCH Aaron Diamond AIDS Research Center 455 First Avenue 7th Floor New York NY 10016 133540234 501(c)(3) 62502 BASIC RESEARCH New England Primate Research Center Harvard Medic Harvard Medical School 25 Shattuck Southborough MA 01772 042103580 501(c)(3) 62502 BASIC RESEARCH University of California San Francisco 533 Parnassus Avenue U442 San Francisco CA 94110 946036493 501(c)(3) 10000 BASIC RESEARCH University of California San Francisco 3333 California Street Suite 315 San Francisco CA 94110 946036493 501(c)(3) 10000 BASIC RESEARCH University of California San Francisco 3333 California Street Suite 315 San Francisco CA 94110 946036493 501(c)(3) 10000 BASIC RESEARCH Johns Hopkins University School of Medicine 733 North Boradway Suite 117 Baltimore MD 21287 520595110 501(c)(3) 10000 BASIC RESEARCH Case Western Reserve University 10900 Euclid Avenue Cleveland OH 44106 341018992 501(c)(3) 10000 BASIC RESEARCH The Salk Institute for Biological Studies 10010 North Torrey Pines Road La Jolla CA 92037 952160097 501(c)(3) 10000 BASIC RESEARCH Vaccine and Gene Therapy Institute of Florida 11350 SW Village Parkway Port St Lucie FL 34987 364631835 501(c)(3) 62502 BASIC RESEARCH University of Washington 4333 Brooklyn Avenue NE Box 35947 Seattle WA 981959472 916001537 501(c)(3) 62502 BASIC RESEARCH Vaccine and Gene Therapy Institute of Florida 11350 SW Village Parkway 3rd Floor Port St Lucie FL 34987 364631835 501(c)(3) 62502 BASIC RESEARCH Case Western Reserve University 10900 Euclid Avenue LC 4930 Cleveland OH 44106 341018992 501(c)(3) 62502 BASIC RESEARCH Beth Israel Medical Center Dazian Building First Avenue at 16 New York NY 10003 135564934 501(c)(3) 37646 PUBLIC POLICY California Institute of Technology 1200 E California Blvd Pasadena CA 91125 951643307 501(c)(3) 124800 BASIC RESEARCH Case Western Reserve University 10900 Euclid Avenue Cleveland OH 44106 341018992 501(c)(3) 124998 BASIC RESEARCH Massachusetts General Hospital 55 Fruit Street Boston MA 02114 042697983 501(c)(3) 124998 BASIC RESEARCH Beth Israel Medical Center - Edmond de Rothschild First Avenue at 16th Street New York NY 10003 135564934 501(c)(3) 22500 PUBLIC POLICY Tulane University 1430 Tulane Avenue EP-15 New Orleans LA 70112 720423889 501(c)(3) 33333 BASIC RESEARCH John Hopkins University Office of Research Administration Baltimore MD 21205 520595110 501(c)(3) 80000 BASIC RESEARCH John Hopkins University Office of Research Administration Baltimore MD 21205 520595110 501(c)(3) 80000 BASIC RESEARCH The Brigham and Women's Hospital Inc 75 Francis Street Boston MA 02115 042312909 501(c)(3) 96397 BASIC RESEARCH University of North Carolina at Chapel Hill 104 Airport Drive Suite 2200 CB Chapel Hill NC 27599 566001393 501(c)(3) 166748 BASIC RESEARCH Johns Hopkins University 733 North Broadway Suite 117 Baltimore MD 21205 520595110 501(c)(3) 351225 BASIC RESEARCH Global Health Committee Inc 200 Longwood Avenue Boston MA 02115 043481920 501(c)(3) 297749 TREAT ASIA Johns Hopkins University School of Medicine 733 N Broadway Street Broadway Res Baltimore MD 21201 520595110 501(c)(3) 46872 BASIC RESEARCH Fred Hutchinson Cancer Research Center 1100 Fairview Ave N C2-187 Seattle WA 98109 237156071 501(c)(3) 46872 BASIC RESEARCH Dana-Farber Cancer Institute Inc 450 Brookline Avenue CLS 1017 Boston MA 02215 042263040 501(c)(3) 46872 BASIC RESEARCH The Scripps Research Institute 10550 North Torrey Pines Road La Jolla CA 92037 330435954 501(c)(3) 46872 BASIC RESEARCH Veterans Medical Research Foundation 3350 La Jolla Village Drive MC 151 San Diego CA 92161 330189397 501(c)(3) 120000 BASIC RESEARCH Universiy of Washington 4333 Brooklyn Ave NE Box 359472 Seattle WA 981959472 916001537 501(c)(3) 120000 BASIC RESEARCH University of California San Francisco 3333 California Street Suite 315 San Francisco CA 94110 946036493 501(c)(3) 114162 BASIC RESEARCH Harvard Medical School 25 Shattuck Street Southborough MA 01772 042103580 501(c)(3) 119200 BASIC RESEARCH Oregon Health and Science University 3181 SW Sam Jackson Park Rd Portland OR 97239 931176109 501(c)(3) 120000 BASIC RESEARCH Vaccine & Gene Therapy Institute Florida 9801 SW Discovery Way Port St Lucie FL 34987 364631835 501(c)(3) 119990 BASIC RESEARCH Baron Edmond de Rothschild Chemical Dep First Avenue at 16th Street New York NY 10003 135564934 501(c)(3) 67500 PUBLIC POLICY AIDS Foundation of Chicago as sponsor of Internati 200 West Jackson Ste 2200 Chicago IL 60606 363412054 501(c)(3) 7500 GMT INITIATIVE Northwestern University 750 N Lake Shore Drive Chicago IL 60611 362167817 501(c)(3) 5850 BASIC RESEARCH Johns Hopkins University Bloomberg School of Publi 615 N Wolfe St Baltimore MD 21205 520595110 501(c)(3) 48500 GMT INITIATIVE Johns Hopkins University Bloomberg School of Publi 615 N Wolfe St Baltimore MD 21205 520595110 501(c)(3) 15107 GMT INITIATIVE Case Western Reserve University 10900 Euclid Ave Cleveland OH 44106 341018992 501(c)(3) 116655 BASIC RESEARCH Vaccine and Gene Therapy Institute Florida 9801 SW Discovery Way Port St Lucie FL 34987 364631835 501(c)(3) 196761 BASIC RESEARCH University of California Los Angeles 11000 Kinross Avenue Suite 211 MC Los Angeles CA 90095 956006143 501(c)(3) 100000 BASIC RESEARCH Johns Hopkins University 733 N Broadway Office of Research Baltimore MD 21205 520595110 501(c)(3) 60000 BASIC RESEARCH Johns Hopkins University School of Medicine 733 North Broadway Street Baltimore MD 21205 520595110 501(c)(3) 20001 BASIC RESEARCH Worldwide Orphans Foundation 515 Valley Street Suite 201 Maplewood NJ 07040 133968225 501(c)(3) 14927 TREAT ASIA Blood Systems Inc dba Blood Systems Research Ins 270 Masonic Avenue San Francisco CA 941184417 860098929 501(c)(3) 42193 BASIC RESEARCH University of Pittsburgh 123 University Place Pittsburgh PA 152132303 250965591 501(c)(3) 102000 GMT INITIATIVE 51 Grants and Assistance Part I, Line 2 amfAR provides grants and fellowships to independent not-for-profit organizations through a peer-review process. Grant applications are first reviewed by the Foundation's volunteer scientific advisory committee, which comprises recognized experts in the medical, scientific, and social sciences disciplines relevant to HIV and AIDS. The scientific advisory committee then sends its evaluations to one of the three committees (research, global initiatives or public policy) of the Foundation's program board, which serves in an advisory capacity to the Board of Trustees. After a program committee has completed its review of the applications, it presents its funding recommendations to amfAR's executive committee and/or the full Board of Trustees for final approval and funding authorization. Grants and fellowships are payable over a one-to-three-year period, and are revocable at amfAR's option if the recipient's performance or use of funds is not consistent with the terms of the grant or fellowships. In certain cases, the actual amounts paid under grants and fellowship awards may be less than the original award if the recipient does not use the full amount awarded. Therefore, a reserve for unexpended grants and fellowships has been recorded. Subawards are grants awarded to not-for-profit organizations to support the costs of collaboration and participation in HIV/AIDS-related research projects for which amfAR has secured restricted funds. Subawards are payable over a one-year period, although advance payments, in full or in part, may be issued following execution of the subaward agreement. Subawards are contingent upon the availability of funds and are revocable if the recipients' performance or use of funds is not consistent with the subaward terms. X X X X false true false false false false false false false Kevin Frost 385700 0 0 0 0 0 69500 0 28683 0 483883 0 Bradley Jensen 217845 0 0 0 0 0 15470 0 31319 0 264634 0 John F Logan JD PhD 203482 0 0 0 0 0 14331 0 10201 0 228014 0 Rowena Johnston 166901 0 0 0 0 0 11736 0 10201 0 188838 0 Edward Donnelly 133796 0 0 0 0 0 9796 0 9043 0 152635 0 Gregory L Boroff 228217 0 0 0 0 0 16218 0 10201 0 254636 0 Christopher Collins 192518 0 0 0 0 0 12720 0 19636 0 224874 0 Annette Sohn 200613 0 0 0 0 0 14082 0 5553 0 220248 0 Eric Muscatell 157089 0 0 0 0 0 11276 0 10201 0 178566 0 Andrew McInnes 134850 0 0 0 0 0 9876 0 31319 0 176045 0 Anthony Ancona 155133 0 0 0 0 0 10935 0 3276 0 169344 0 Susan Doster 132775 0 0 0 0 0 9277 0 10201 0 152253 0 AnnMarie Shannahan 194344 0 0 0 0 0 13671 0 10201 0 218216 0 Bennah Serfaty 120255 0 0 0 0 0 7992 0 31319 0 159566 0 Compensation Part I, Line 4 Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan; however, he did not receive a distribution in 2013. X 1 56250 appraisal X 14 47853 sales price false true true Form 990, Schedule M Line 31: To the extent that amFAR receives non-standard contributions, the organization's policy is to liquidate those items into cash for eventual use in support of the organization's mission. Line 32A: When the organization receives contributions of securities, it uses its investment broker to liquidate those holdings to fund amFAR's various research program activities. Program Service Accomplishments(1) Part III, Line 4a-4d(1) Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2013, amFAR awarded nearly $4 million in grants and fellowships to support 20 research projects. Cure-Focused Studies The Search for a cure for HIV/AIDS is at the center of amFAR's research efforts. In 2013, through the amFAR Research Consortium on HIV Eradication (ARCHE) program-now in its fourth year of funding-and other targeted grants, the Foundation awarded nearly $3 million for cure-focused research. First Child Cured of HIV At the Conference on Retroviruses and Opportunistic Infections in March 2013, Dr. Deborah Persaud of John Hopkins Children's Center detailed the case of a two-year-old child in Mississippi who had been cured of HIV. Confirmation of the cure was made possible by a grant amFAR awarded to Dr. Persaud and her colleague Dr. Katherine Luzuriaga of the University of Massachusetts Medical School in September 2012. The grant allowed them to establish a research collaboratory to explore and document possible pediatric HIV cure cases. amFAR Research Consortium on HIV Eradication The Foundation launched the ARCHE program in 2010 as a way to leverage the expertise and innovation of distinguished scientists from across the globe to advance cure-focused research. In July, more than $1.4 million in funding went to four collaborative teams of researchers working in the United States, the United Kingdom, France, Thailand, and Australia on studies exploring potential strategies for eliminating HIV infection from the body and characterizing viral reservoirs-which present a major obstacle to a cure. One study, led by Dr. Eric Arts of Case Western Reserve University in Cleveland, Ohio, aims to develop and test a vaccine-like HIV treatment specific to each patient's virus. Unlike other approaches toward an HIV cure that focus on inducing cell changes in all cells that are vulnerable to HIV infection, this treatment specifically targets the infected cells lying dormant in teh viral reservoir. Dr. Arts and Dr. Yong Gao from Case Western is working wiht Drs. Robin Shattock, Sarah Fidler, and Caroline Foster of Imperial College London to study the treatment's effectiveness. In another study, a team led by Dr. Nicolas Chomont of the Vaccine and Gene Therapy Institute in Port St. Lucie, Florida, is studying HIV persistence in T cell subsets during antiretroviral therapy (ART). Specifically, they are investigating the subsets of CD4+ T memory cells-the cells where the HIV reservoir mainly resides-and the roles they may play as a potential target for a cure. Dr. Chomont is working in collaboration with three-time ARCHE grantees Dr. Darah Palmer of University of Sydney, Australia, and Dr. Steven Deeks of the University of California, San Francisco (UCSF); Dr. Jintanat Ananworanich from the Red Cross AIDS Research Centre in Bangkok, Thailand; and Dr. Asier Saez-Cirion of Institut Pasteur in Paris, France. Targeted Grants for HIV Cure Research In February 2013, amfAR awarded eight targeted grants totaling more than $1.4 million to leading researchers from around the world who are working on a variety of cutting-edge, cure-focused studies. These projects include research aimed at therapeutic vaccine development, expanding our understanding of latent viral reservoirs, and examining pharmacological and gene therapy approaches to curing HIV. Dr. Jonah Sacha of the Oregon Health and Science University, in Portland, is examining the macrophage-an immune cell that is closely related to the T cell-for its potential role in maintaining hidden reservoirs of HIV. Dr. Sacha and colleagues propose to directly assess the function of macrophages in viral persistence in a non-human primate model of AIDS. Understanding the macrophage's contribution will guide future approaches to eliminating residual viral reservoirs. Program Service Accomplishments(2) Part III, Line 4a-4d (2) Line 4a, Continued: Although the immune system can greatly reduce levels of virus after infection, it cannot maintain this control indefinitely. Therapeutic vaccines, which are currently being designed and tested, may enable patients to stop taking ART without progressing to disease. Dr. Christian Brander at Irsicaixa AIDS Research Institute, Badalona, Spain, and his colleagues plan to closely monitor changes in immune function after patients-who are currently enrolled in a therapeutic vaccine clinical trial-stop taking their anti-HIV medication. Their findings will help guide the design of more effective therapeutic vaccines and may also enable researchers to predict which individuals will respond best in future trials. Therapeutic vaccines may one day play an important role in achieving sustained remission of HIV. Another study, led by Dr. Satish Pillai at UCSF is examining how an unusual genetic mutation-CCR5-delta32-may enhance the curability of HIV. He will measure the amount of virus that persists in patients with or without this mutation. Applying cutting-edge laboratory techniques, Dr. Pillai's team will compare the size, composition, and decay of the HIV-1 latent reservoir in individuals with and without the mutation. Gene therapy approaches are being investigated as a means of curing HIV. One strategy that has shown promising results uses a gene therapy method to modify a patient's own cells in the laboratory to make them resistant to virus infection. Dr. Rafick-Pierre Skaly, at the Vaccine and Gene Therapy Institute in Port St. Lucie, Florida, will build on the current work being done using this approach to determine if virus becomes undetectable in the blood after stopping ART. He will monitor immune responses, inflammation, and viral reservoirs in a group of patients to ascertain the long-term benefit of this therapy and factors that can improve outcomes of gene therapy and other strategies to cure HIV. Mathilde Krim Fellowships Four researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2013 Krim Fellows-each of whom received $125,000-are working on projects focused on HIV/AIDS cure and epidemiological research and vaccine and treatment development. Among the 2013 fellows is Dr. Leopold Kong, Ph.D., of the Scripps Research Institute in California, who will attempt to develop a vaccine using the protective coating of sugar-like molecules that surround the virus. This coating is traditionally thought to hamper the development of antibodies that might form the basis of a vaccine. Dr. Kong will determine whether this protective coat can instead be turned against the virus to render it vulnerable to destruction by the body's immune system. His research will determine if antibodies generated against these sugars can be used to develop a vaccine that can prevent infection. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 48 scientific publications resulted from amfAR-funded research. Perfecting Tools to Monitor HIV Viral Loads In the March issue of Current Opinion in HIV and AIDS, ARCHE-funded scientist Dr. Sarah Palmer of the University of Sydney, Australia, reviewed the state of knowledge in the detection and monitoring of HIV levels in the blood of infected people. She emphasizes the importance of early ART initiation and the value of monitoring blood HIV RNA levels to ensure the virus is suppressed to below the detection capacity of standard tests. Dr. Palmer goes on to discuss the demand for ultrasensitive virus detection methods and notes that such assays, which can find a single copy of the virus in a milliliter (about a fifth of a teaspoon) of blood, can also be used to document viral "blips," or transient, low-level bursts of virus. She believes these methods will enable researchers to define the source of persistent virus in people on long-term ART, and recently started using the techniques to assess the efficacy of treatment strategies by which latent HIV is chemically coaxed out of a person's infected cells, rendering them vulnerable to attack by ART. Controlling HIV after Stopping Antiretroviral Therapy People with HIV who are successfully treated with ART still have infected cells in which the virus remains silent and invulnerable to attack by the immune system or standard anti-HIV drugs. This is a critical barrier to curing HIV. Several studies show that virus growth quickly returns, in most individuals, within weeks of stopping treatment. In the January issue of the Journal of Infectious Diseases, Dr. Steven Deeks of UCSF, Dr. Una O'Doherty of the University of Pennsylvania, and colleagues described a clinical trial that used a special form of interferon, known as pegylated interferon (PEG-IFN) alpha-2a to suppress the typical rebound in viral growth that occurs after halting ART. They found that 45% of their patients maintained viral loads of less than 400 copies-an amount significantly less than what was expected based on prior treatment interruption studies-when given PEG-IFN in addition to ART before having the ART withdrawn. Four of the subjects had "undetectable" viral loads-less than 48 copies-and stayed off all therapy except the PEG-IFN for a full six months. The authors conclude that they have established "a proof of concept" that HIV growth can be markedly suppressed in people in whom the "detrimental effects of uncontrolled HIV replication on immune function have been partially reversed by ART." Perfecting Gene-Based Therapies Targeting HIV Gene therapy-the use of genetically altered immune cells-is a promising approach to curing HIV/AIDS. However, the cost and potential side effects, which include death, of such an invasive procedure render it inappropriate for most individuals living with HIV. In the April issue of Molecular Therapy, amfAR grantees Dr. Matthew Porteus of Stanford University and Dr. Sara Sawyer of the University of Texas at Austin suggested a safer and potentially more accessible approach-using a person's own genetically modified immune cells. They used an enzyme known as a zinc finger nuclease to insert a cocktail of anti-HIV factors into T cells. The technique mimics the cocktail of anti-HIV drugs used with ART. When all of the factors were present, it provided "virtually complete protection" against infection by the two major strains of HIV-1, R5 and X4. The next step is to perform the same procedure not just in laboratory grown T cells, but in a patient's own immune cells-either T cells or, ultimately, stem cells. Program Service Accomplishments (3) Part III, Line 4a-4d (3) Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 23 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 8,526 patients at 23 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. In 2013, the TAHOD network began recruiting participants for a regional study of hepatitis C co-infection among those living with HIV in four countries: Indonesia, Malaysia, Thailand, and Vietnam. The study began with a screening study to assess how many HIV-positive patients in TREAT Asia participating clinics in these countries need to start treatment for hepatitis C. TREAT Asia will then offer up to 200 of these patients hepatitis C treatment for free. The study aims to develop a pilot model of care for treating hepatitis C in resource-limited settings that can be replicated throughout the region, where treatment for the disease is costly and often inaccessible. TREAT Asia Pediatric Network TREAT Asia's Pediatric Network includes 20 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult database, and includes data from approximately 5,030 pediatric patients at 18 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. Adolescent Research In 2013, TREAT Asia conducted several studies on how HIV affects adolescents physically, socially, and emotionally. TREAT Asia's pediatric sites conducted local studies among their adolescent HIV patients to investigate HIV's impact on their health. Among other issues, they assessed cardiovascular function, bone mineral density, incidence of human papillomavirus, models for reproductive healthcare, and optimizing drug adherence. In addition, TREAT Asia is conducting an ongoing study using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface about whether they are taking their medicines; if they have tried alcohol, tobacco, or other drugs; their sexual behavior; and stigma they may have experienced at school or at home. Exploring Links Between HIV and Cancer Among HIV-positive MSM, the risk of anal cancer is twice as high compared to those who are HIV-negative, but little research has been done on this issue in Asia. In 2009, using funding from IeDEA, TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Research on HPV and anal cancer risk among MSM is ongoing in the three original sites in Bangkok, Bali, and Jakarta. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized five workshops and training sessions in 2013, including sessions on managing HIV and hepatitis C co-infection, good clinical practices and research ethics, and clinical management of pediatric HIV. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community-friendly" educational brochures on HIV treatment standards in local languages. In 2013, TREAT Asia developed a series of educational materials about hepatitis C infection and treatment titled Life Loves the Liver that includes animated video segments, booklets, and flip charts. All materials have been developed in Bahasa Indonesia, Chinese, English, Malay, Thai, and Vietnamese and will be distributed to TREAT Asia's local, national, regional, and global partners. They will also be made available on TREAT Asia's internal webpage and its public YouTube channel. TREAT Asia also continued to publish lay-language articles about new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention TREAT Asia was well represented at the conference in June 2013 in Kuala Lumpur, Malaysia. In addition to activities during the main conference, TREAT Asia staff and network investigators participated in pre-conference workshops on HIV pediatric and cure research. At the pediatric workshop, a TREAT Asia study was presented on the correlation between HIV drug levels in hair samples and virus control outcomes, and Dr. Annette Sohn, amfAR vice president and director of the TREAT Asia program, participated in a debate on the need for pre-exposure prophylaxis for youths at risk of HIV. At the main conference, TREAT Asia studies were presented on the long-term impact of perinatally acquired HIV infection and antiretroviral therapy in adolescents, the prevalence of hepatitis B and C co-infections among adults in TREAT Asia's regional HIV research network, and the risk of anal cancer among men who have sex with men in Thailand and Indonesia. 16th Bangkok Symposium on HIV Medicine amfAR continued its sponsorship of this annual regional symposium, which was held in January 2013 in Bangkok. Dr. Sohn spoke about human papillomavirus infection among HIV-infected youths. TREAT Asia also supported a special workshop during the symposium on the challenges faced while transitioning perinatally infected children to adult HIV care. Program Service Accomplishments (4) Part III, Line 4a-4d (4) Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research on HIV/AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 5,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than100,000 people. The Foundation's newly redesigned website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public. The Battle of amfAR amfAR helped promote and organize screenings of The Battle of amfAR, a documentary film telling the story of how Swiss scientist Dr. Mathilde Krim and Hollywood movie star Elizabeth Taylor joined forces to create amfAR in 1985. The film played at prominent film festivals throughout 2013 and was an Official Selection at the Sundance and Tribeca Film Festivals. It premiered on HBO in December 2013. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV/AIDS. The Foundation regularly added content to its Facebook page, created an Instagram account, and live tweeted and posted images on Instagram from fundraising and program events. amfAR passed 45,000 likes on Facebook in 2013 and now has nearly 20,000 Twitter followers and nearly 6,000 Instagram followers. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including The New York Times, The Wall Street Journal, The Washington Post, the Associated Press, Reuters, Bloomberg News, CNN, and The Huffington Post. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In 2013, celebrity supporters included amfAR ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Leonardo DiCaprio, Heidi Klum, Alan Cumming, Aishwarya Rai, Abhishek Bachchan, Ke$ha, Gladys Knight, Jessica Chastain, Dame Shirley Bassey, Hilary Swank, Kylie Minogue, Duran Duran, Rosario Dawson, Rosie Perez, Zachary Quinto, Adrien Brody, Dita Von Teese, Preta Gil, Chelsea Handler, and Carly Rae Jepsen, among many others. Program Service Accomplishments (5) Part III, Line 4a-4d (5) Line 4d: THE GMT INITIATIVE: Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR helps expand access to HIV education and prevention services; supports advocacy aimed at increasing funding for prevention and treatment services; and works to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS. Community Awards In 2013, amfAR awarded more than $710,000 to 39 groups in Africa, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Sample funded projects include: Africa Men Against AIDS Youth Group (MAAYGO) (Kisumu, Kenya) MAAYGO is conducting a needs assessment among GMT community members, health and social service providers, micro-credit institutions, and employers in order to better understand barriers to economic empowerment and improved health outcomes for GMT. The results of the assessment will be used to increase access to health services by helping health and social service providers to create GMT-friendly environments. In addition, MAAYGO will promote economic independence for GMT through job skills trainings and a GMT-focused micro-credit program. Caribbean Kouraj (Port-au-Prince, Haiti) Kouraj will organize a training program to educate key GMT leaders on human rights. These same leaders will also receive training in basic research techniques so they can conduct a series of interviews with GMT to document and better understand the level of human rights abuses and violence GMT experience. The information collected from these interviews will be analyzed and used to develop a human rights brief that will serve as a tool to advocate for greater inclusion of GMT in national discussions on HIV and health, as well as to advocate for reduced stigma and discrimination against GMT. Eastern Europe and Central Asia Safe Pulse of Youth (SPY) (Belgrade, Serbia) SPY is increasing the number of GMT individuals tested for HIV and other sexually transmitted infections through the use of a mobile testing van and at its drop-in center "BGD Checkpoint." SPY will also strengthen linkages to mental health and social support services for GMT living with HIV in Belgrade and document and disseminate cases of stigma and discrimination experienced by GMT in public and private healthcare institutions. Latin America Asociacin Solidaria Para Impulsar el Desarrollo Humano (ASPI-DH) (San Salvador, El Salvador) In its second year as an amfAR grantee, ASPI-DH will expand its "Open Road 2011" project to additional regions in El Salvador and will continue training healthcare providers at 24 public health centers across the country on the needs of GMT people. ASPI-DH will focus on reducing stigma and discrimination within health centers in an effort to encourage uptake of HIV prevention, treatment, and care for GMT. This will be accomplished by organizing "Open Door" days at the centers that have participated in the trainings. ASPI-DH will also deploy patients as undercover evaluators or mystery clients who will visit the centers in order to evaluate the quality of care. "In Action" Awards The GMT Initiative also made three awards as part of its Advocacy in Action program, which supports GMT-led community-based organizations that wish to influence the policies of governments and external donors. Four awards were made under its Evidence in Action program, which documents and evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare's Positive Action Program and the Elton John AIDS Foundation. Awards for these two programs in 2013 totaled approximately $150,000. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among GMT and to advocate for effective strategies to address it, amfAR publishes a range of reports. In May 2013, amfAR published Achieving an AIDS-Free Generation for Gay Men and Other MSM in Southern Africa with the Johns Hopkins Bloomberg School of Public Health. This report details how underfinancing, discrimination, and stigma undermine efforts to address HIV among GMT in the region and makes recommendations about how policymakers can better address the needs of GMT. Individual country profiles on Botswana, Malawi, Namibia, Swaziland, Zambia, and Zimbabwe were also produced to supplement the report. The GMT Initiative Blog, Grassroots, posted articles throughout the year that discuss various HIV-related issues the GMT Initiative's grantee partners are facing and how these issues impact their lives and organizations. Technical Consultation on Innovative Uses of Communication Technology for HIV Programming for MSM and Transgender Populations amfAR co-hosted this meeting in Washington, D.C., May 2-3, 2013, in partnership with the President's Emergency Plan for AIDS Relief (PEPFAR) and USAID. During the meeting, attending activists from around the world were linked with technical leaders and program planners from the U.S. who are working to combat the HIV epidemic among GMT internationally. Prior to the meeting, amfAR hosted a skills-building session for five GMT Initiative grantees that offered them strategies to increase their programs' effectiveness. Program Service Accomplishments (6) Part III, Line 4a-4d (6) Line 4d: Public Policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill Briefings Where Are We in Ending the AIDS Epidemic? An Update on the Science, July 18, 2013 amfAR, along with IDSA Center for Global Health Policy and the Elizabeth Glaser Pediatric AIDS Foundation, co-sponsored two briefings that featured leading researchers discussing the latest research on core evidence-based interventions for achieving an AIDS-free generation. Speakers were Dr. Myron Cohen of the University of North Carolina at Chapel Hill, Dr. Laura Guay from the Elizabeth Glaser Pediatric AIDS Foundation, Dr. Renee Ridzon of Akeso Associates, and Dr. Chris Beyrer of the Johns Hopkins Bloomberg School of Public Health. Prescription Opioids, Heroin and Disease Prevention: Law Enforcement, Research, and Community Perspectives, July 23, 2013 The briefing highlighted the need to overturn the ban on federal funding for syringe services programs (SSPs) in the face of an alarming increase in injection drug use in the United States. SSPs are essential for combating the spread of HIV through the sharing of contaminated needles. A short film produced by amfAR, titled The Exchange (see below), was screened and followed by a discussion of program and policy issues critical to advancing public safety and health. Speakers included Seattle Police Chief Jim Pugel, Dr. Jennifer Havens of the University of Kentucky, and Kristin Dubay Horton of the Bridgeport (CT) Health Department. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for people who inject drugs (PWID), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving HIV prevention programs. Addressing the need to overturn the ban on federal funding for syringe services programs, amfAR produced four short films on the wide-ranging public health and economic benefits of SSPs and launched a new website designed to educate policymakers and the public on the urgent need for these programs. Additionally, amfAR's policy office produced a number of issue briefs and fact sheets addressing HIV among PWID and the value of SSPs to this high-risk population, including a map of SSP coverage in the United States. In July, amfAR hosted a two-day think tank on implementation science for PWID. There are highly effective interventions for preventing HIV transmission and acquisition among PWID, but coverage levels remain low, stymied by counterproductive policy and legal frameworks, as well as by a lack of access to individuals in need of services. Some key points of discussion during the event included using implementation science to increase our understanding of how to reach and retain PWID with currently available programs and technology, efforts to distribute low dead space syringes (which have been shown to reduce HIV and hepatitis C transmission among PWID), and addressing mental illness and social issues surrounding drug use (e.g., homelessness). Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the epidemic in the U.S., where more than one million people are living with the virus. In August, the Public Policy Office contributed an opinion piece to the Huffington Post by amfAR Chairman Kenneth Cole and Rep. Barbara Lee (CA) observing the third anniversary of the National HIV/AIDS Strategy. The editorial summarized progress over the last three years on tackling the AIDS epidemic domestically and called for a renewed commitment by providers, advocates, and policymakers to realize the vision of an AIDS-free generation. Additionally, amfAR produced a number of issue briefs, fact sheets, and infographics showing how cuts to domestic HIV/AIDS programming and research funding through federal sequestration undermine the domestic response to the epidemic. Global Health At the International AIDS Conference in 2012, amfAR released "An Action Agenda to End AIDS," developed with AVAC, to identify major short-term priorities for global AIDS programs together with realistic, annual targets through 2016, in an effort to establish a strong, sustainable foundation for ending AIDS. In 2013, one year after the conference, amfAR produced a follow-up report assessing the world's progress to date. The report describes progress being made in certain key areas, including increases in the total number of people on ART, the amount of pregnant women living with HIV who received antiretroviral medication, the number of men circumcised, and the estimated number of people eligible for ART under new therapy guidelines. The report also identifies areas where the global AIDS response is falling short, including persistent coverage gaps in scaling up core interventions, widespread stigma and discrimination, and inadequate access to key diagnostic tools. Additionally, in 2013, amfAR reported extensively on the impact of budget sequestration on global health, with specific attention to how funding cuts to the President's Emergency Plan for AIDS Relief (PEPFAR)-would undermine the decade's worth of progress made by the largest international response program to the global AIDS epidemic. GMT Gay men, other men who have sex with men, and transgender individuals-collectively referred to as GMT-remain one of the hardest hit and most underserved populations in the global HIV/AIDS epidemic. amfAR's policy office works closely with the Foundation's GMT Initiative to advocate for expanded access to HIV prevention and treatment services for GMT worldwide, and to fight the stigma and discrimination that make GMT more vulnerable to HIV infection and inhibit equal access to care. In May, amfAR released a new report-Achieving an AIDS-Free Generation for Gay Men and Other MSM in Southern Africa-on funding and policy related to tackling the HIV epidemic among gay men and other MSM in Southern Africa (see GMT Initiative). An issue brief released by amfAR in August, titled Tackling HIV/AIDS Among Key Populations: Essential to Achieving an AIDS-Free Generation, argues that ending the AIDS pandemic will not be possible without greatly increased efforts to reduce new infections and prevent AIDS-related deaths among key populations at highest risk of HIV. The brief reports that key populations (including GMT) are severely and disproportionately affected by HIV on a global level-with epidemics among these individuals continuing to grow despite an overall decline in new infection rates-and that they are largely neglected by HIV treatment and prevention efforts as a result (directly and indirectly) of discriminatory laws and policies. The issue brief highlights a few of the evidence-based strategies that are available to substantially reduce the number of new infections and AIDS-related deaths among key populations. Policies Form 990, Part VI, Section B Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 -AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. Disclosure Form 990, Part VI, Section C LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion. Functional Expenses Part IX, Lines 1 & 3 The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F. Other Changes in Net Assets FORM 990, SECTION XI, LINE 9 CHANGE IN VALUE OF THIRD PARTY TRUST................ ($29,887) ---------- TOTAL LINE 9 ($29,887) ==========